<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1474">
  <stage>Registered</stage>
  <submitdate>19/07/2006</submitdate>
  <approvaldate>26/07/2006</approvaldate>
  <actrnumber>ACTRN12606000320550</actrnumber>
  <trial_identification>
    <studytitle>Zileuton therapy for Sjogren-Larsson syndrome</studytitle>
    <scientifictitle>Randomised crossover trial to evaluate the effects of Zileuton in patients with Sjogren-Larsson syndrome assessing potential benefit in terms of symptoms (itch), biochemical and neuropsychological indices</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Sjogren-Larsson syndrome</healthcondition>
    <conditioncode>
      <conditioncode1>Human genetics and inherited disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Zileuton treatment, orally, dosage by weight:
12.5-18.75 kg:   300 mg twice a day
18.75-25 kg:      300 mg three times a day
25-37.5 kg:        300 mg four times a day
37.5-50 kg:        600 mg hree times a day
&gt;50 kg:             600 mg qds
Patients provide their own internal control as crossover trial with treatment/placebo periods of 3 months separated by a one month wash out period.</interventions>
    <comparator>No comparator.</comparator>
    <control>Placebo</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Itch scores</outcome>
      <timepoint>At O, 3, and 7 months (crossover period), and 19 months (open label)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Clinical neuropsychological evaluation</outcome>
      <timepoint>At O, 3, and 7 months (crossover period), and 19 months (open label)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>EEG</outcome>
      <timepoint>At O, 3, and 7 months (crossover period), and 19 months (open label)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>MRI/MRS</outcome>
      <timepoint>At O, 3, and 7 months (crossover period), and 19 months (open label)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Lack of adverse side effects of treatment. </outcome>
      <timepoint>At 7 months or 19 months if choose participate in the open label extension.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Paediatric patients with a clinical diagnosis and biochemically confirmed Sjogren-Larsson syndrome. </inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>16</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria> Adult patients.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation by computer</concealment>
    <sequence>Simple randomisation by computer software</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/08/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>3</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>South East Sydney Area Health Service</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Sydney Children Hospital</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Critical Therapeutics Inc</fundingname>
      <fundingaddress />
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Sydney Children's Hospital</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is find out whether zileuton helps to improve the symptoms of children with SLS in terms of skin symptoms (itch), neurology and motor function.
patients, parents, investigators and asessors blinded - only central pharmacy will be aware of whether the patient is on placebo or treatment at the time (open label period excepted).</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sydney Children's Hospital, part of South East Sydney and Illawarra Area Health Service</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>02/071</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Jason Pinner</name>
      <address>Department of Medical Genetics
Sydney Children's Hospital
High Street
Randwick NSW 2031</address>
      <phone>+61 2 93821704</phone>
      <fax />
      <email>Jason.Pinner@sesiahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Edwin Kirk</name>
      <address>Department of Medical Genetics
Sydney Children's Hospital
High Street
Randwick NSW 2031</address>
      <phone>+61 2 93821704</phone>
      <fax />
      <email>Edwin.Kirk@sesiahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>